2024-10-24 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**1. Performance Relative to S&P 500 (VOO)**

AbbVie Inc. (ABBV) has outperformed the S&P 500 (VOO) with a cumulative return of 142.51% compared to VOO's 136.39%. The current outperformance is 6.12%,  which represents a relative outperformance of 48.52% when compared to the historical range of outperformance (max: 56.45%, min: -41.78%).

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company developing and commercializing innovative medicines across several therapeutic areas, including immunology, oncology, neurology, and eye care.

**2. Recent Price Movement**

| Indicator | Value |
|---|---|
| Closing Price | 186.58 |
| 5-Day Moving Average | 188.2 |
| 20-Day Moving Average | 192.85 |
| 60-Day Moving Average | 193.13 |

The stock price is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a short-term downtrend.

**3. Technical Indicators Analysis**

| Indicator | Value | Interpretation |
|---|---|---|
| RSI | 21.76 |  Indicates the stock is oversold. |
| PPO | -0.51 |  Suggests a bearish momentum in the short-term. |
| Delta_Previous_Relative_Divergence | -12.77 |  Suggests a recent short-term downtrend. |
| Expected_Return | 5.4% | Suggests an estimated 5.4% long-term (2+ years) outperformance compared to the S&P 500 with a long-term investment strategy. |

**4. Recent Earnings and Outlook**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

AbbVie has consistently exceeded earnings expectations in recent quarters. The most recent earnings report (2024-07-25) showed an EPS of 2.65 exceeding the expected EPS of 2.57, indicating a positive performance.

**5. News and Recent Issues**

Recent market outlook for ABBV is mixed, with analysts citing concerns about potential patent expirations for Humira, AbbVie's flagship drug, while recognizing the company's strong pipeline and robust growth in other segments.

**Analyst Opinions and Performance Highlights:**

* **FINBOLD:**  Highlights AbbVie's impressive revenue growth and strong financial performance, predicting continued growth in the coming years.
* **MarketBeat:** Indicates a consensus “Moderate Buy” rating from analysts, with an average price target of $190.61.

**6. Summary**

AbbVie Inc. (ABBV) has consistently outperformed the S&P 500, showing robust growth in recent years. While the stock is currently trading below its moving averages, indicating a short-term downtrend, technical indicators suggest an oversold condition. The company's recent earnings have surpassed expectations, and its pipeline remains strong. Analyst opinions are generally positive, anticipating continued growth. Long-term investors with a horizon of two years or more might consider investing in ABBV, given the potential for continued outperformance.

**7. Conclusion**

AbbVie Inc. (ABBV) presents a compelling investment opportunity for long-term investors seeking growth and potential outperformance compared to the broader market. However, investors should monitor the company's performance, particularly regarding the impact of Humira's patent expirations. 
